Physicians view Metformin as Leading Combination Treatment Option for Type II Diabetes: companiesandmarkets.com

• Insulin classes include: Basal insulins, Prandial insulins, Intermediate-acting insulins and Premixed insulins
• Insulin therapies are usually offered as a third-line approach to diabetes treatment, and then as a combination treatment
• Oral drugs are preferred to treat diabetes in the UK and France with only 22% patient share using insulin. In Germany, 43% of patients use insulin for controlling diabetes

LONDON--(BUSINESS WIRE)--Insulin is used as a therapeutic treatment for type II diabetes for over a third of patients living in France, Germany, Italy, Spain, the UK and US. Market share varies significantly between countries, with a higher percentage of German diabetics using insulin (43%), compared with the UK and France (22%), where patients have a preference for oral administration of drugs, according to a new report available on companiesandmarkets.com.

Hot Topics in Type 2 Diabetes: Physician Perceptions of Insulin - Physician survey provides insights into insulin usage and needs

http://www.companiesandmarkets.com/Market-Report/hot-topics-in-type-2-diabetes-physician-perceptions-of-insulin-physician-survey-provides-insights-into-insulin-usage-and-needs-621390.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The use of insulin to treat Type II diabetes is likely to increase in future, according to this Type II diabetes research report which has surveyed nearly 200 physicians for their views on the treatment.

Basal insulins are reported to hold the largest class share of the insulin market, followed by prandial insulin. Analog insulins (which are an altered form of naturally occurring insulin) are understood to dominate the marketplace, pushing out older classes of type 2 diabetes treatment.

Lantus, a basal insulin, is the highest prescribed brand of insulin for Type II diabetes and is taken as a daily injection, although the report indicates that the response from each individual patient has to be taken into consideration before type II diabetes therapies are prescribed.

Physicians in geographical regions with a higher use of insulin also tend to prescribe it at an earlier stage than other countries.

The 54 page report, published in June 2011, provides the reader with an explanation of the insulin market, particularly in terms of the practices employed in terms of prescribing treatment for type 2 diabetes patients. The analysis is split by geography: France, Germany, Italy, Spain, the UK and US; by therapy line and by insulin class.

Trends, patient compliance and unmet needs are also discussed in depth.

Report Details:

http://www.companiesandmarkets.com/Market-Report/hot-topics-in-type-2-diabetes-physician-perceptions-of-insulin-physician-survey-provides-insights-into-insulin-usage-and-needs-621390.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2